Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 220 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo... June 10, 2025 To Combat Cancer Treatment Resistance, Researchers Try Leveraging Evolution August 22, 2024 Breast Cancer Patient Who Continued Teaching Throughout Her Treatment Wins Teacher... February 9, 2021 FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection October 2, 2024 Load more HOT NEWS Do Black Lives Matter Less Than Those of Cancer Survivors? Girls Aloud members to join forces to raise money in Sarah... Mother and Daughter Graduate Nursing Masters Programs Together After Breast Cancer... How we can reduce cancer risk in inflammatory bowel disease patients...
